Thu, Jul 31, 2014, 8:15 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Protalix BioTherapeutics, Inc. (PLX) Message Board

biommm 10 posts  |  Last Activity: Jul 30, 2014 4:13 AM Member since: May 13, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biommm biommm Jul 30, 2014 4:13 AM Flag

    That is true, perhaps that what will happened.
    In any case, lately we are seeing more and more numerous publications that promote the future of cellular therapy.
    No doubt Pluristem will be a key company in this important segment.
    There is currently a large price gap between the market price and the true potential of the company.
    Those who have patience will be rewarded in the future

    Sentiment: Strong Buy

  • We have the early-stage products in Phase I. The one that I think is perhaps most trans-formative is our cell therapy product. As I know you know from being a keen observer of the industry, I think most people would kind of feel that cell therapy is the mAbs of like the last decade. Like 10, 15 years ago, there really were scarcely any approved monoclonal antibodies. Now they are becoming a mature product class. Cell therapy is there today where mAbs were 10 years ago, and we are pouring significant resources into advancing our cell therapies forward for pulmonary hypertension. The one which I think you probably maybe most familiar with is our license of Pluristem's cell therapy product for pulmonary hypertension. And I'm not completely sure if we've previously announced that, that's now dosing patients in Phase I

    Sentiment: Strong Buy

  • Reply to

    Note from Buteo: To all Pluristem longs.

    by buteo77004 Jul 16, 2014 1:33 AM
    biommm biommm Jul 16, 2014 1:45 AM Flag

    So very true and accurate

  • biommm biommm Jul 15, 2014 3:41 AM Flag

    This was stated in one of Pluristem presentations in Israel. It was not stated as a major event but more as Anecdotal and I do not think it refers to the last months.

    Pluristem has a very clear policy to have collaborations per each indication.
    For this reason after the approval of orphan drug status in Preeclampsia, there is a reasonable chance that we shall hear about one.

    Sentiment: Strong Buy

  • biommm biommm Jul 14, 2014 7:01 AM Flag

    Part 2 : biomedical conference in MIBI - FXG College.

    "It may sound like science fiction, but as of today we proved experimentally in animals, our cells injected traumatized animal screening, blood circulation problems, diabetes, etc. ... Our cells are changing the profile of provisions to carry out the treatment. Therefore, we believe in this medicine era.

    "Our focus this understanding of how to produce cells and how you educate them to do what you want, and then we use in pharmaceutical our reseller and currently we have two customers. Every transaction to have happen later will strengthen our model and our claim and we hope as they multiply like that."

    Sentiment: Strong Buy

  • biommm biommm Jul 14, 2014 4:30 AM Flag

    Pluristem : Arbitrage gap now - nearly 5%.

  • Zami Aberman - Pluristem CEO said in biomedical conference in MIBI - FXG College.
    Aberman added : it all begins and ends with the strategy and the moment you want to be an Israeli company which is a world leader, you must produce your product. You cannot sell knowledge.
    Pluristem want to be an a world leader in development and cell therapy manufacturing and today is the largest company in terms of manpower with 160 employees and only company in the field, which has its manufacturing plant who can produce in terms of sales up to a billion dollars a year, and those two things very rare and unique .
    Pluristem is also traded on the NASDAQ and Tel Aviv,. Aberman noted at the conference that Pluristem is the first and to date the only one who developed technology for producing three-dimensional cells. The technology was acquired from the Weizmann Institute and the Technion in 2007 - to enable commercialization and transactions to date two of them. As it has 27 patents and intellectual property much. The company has a cash equivalent of $ 59 million, when the last report was 49 but after a deal with Korean CEA she added another $ 10 million, so it has quite a lot of money to manage clinical programs.

    Zami explained that Pluristem has proved to be injected muscle stem cells anywhere in the body and get a positive systemic effect on the patient and it changes some things are done. "Our process begins at birth, the placenta. We take the remainder stays, medical waste, and proved to be realized from stem cells of various types.

  • : ( Google translate) Stem Cell Research: Human placenta project is underway: which Israeli company will benefit Big?
    National Institute of Health of the United States decided to launch the "human placenta Project" . What analyst Sharon di Stefano think about that? :

    National Institute of Health of the United States decided to establish the "Project of Human placenta". Perspective of the company Pluristem stem cells, this is good news and positive recognition of the Company's activities on the basis of a technology-based company and manufacture stem cells (PLX).
    Reference to the subject given last weekend analyst biomed assessed Sharon di Stefano who reviews the sympathetic PLURISTEM notes that "for the first time in medical history, the placenta, which usually is an organ underestimated or ignored, will be the centerpiece of a project funded by the government, organ may be necessary to combat diseases humanity ".

    Human placenta project is expected to encompass dozens of experts in the fields of gynecology, children, geneticists and researchers placenta. The experts are expected to discuss the healing potential of the various parts of the placenta.

    PLURISTEM: "a key element in the project" Di Stefano reviewing marks the PLURISTEM candidate has the potential to displace the initiative: "PLURISTEM, its clinical research revolves around restorative medicine derived cells in the placenta, may become a central pillar in the project."

    She says, "The very construction of the project is supporting and strengthening the research direction of Pluristem and even notes that the initiative could draw important information research carried out PLURISTEM so far."

    Yaki Yanai, President of Pluristem responded the article saying that: "it is a further recognition capability of the human placenta, which until recently was considered primarily medical waste."

    He said, "We are so pleased that the NIH established this important project devoted entirely to the Study of

    Sentiment: Strong Buy

  • New Article in Globes -05/04/2014 (the biggest financial newspaper in Israel) - Google Translate
    Recall that in May 2013 the company announced good results in pre-clinical trials examined the effect of stem cells from the placenta of animals which have produced mode simulates human preeclampsia. The study showed that one-time use stem cells from the placenta during pregnancy could restore blood pressure and kidney function to normal levels safely and effectively in preeclamptic mice without any adverse effect on the mother or fetus.

    Additionally note that investment in promoting legislation in the U.S. Senate restorative medicine this year may accelerate the programs and funding in Cellular Medicine.

  • New Article in Globes -05/04/2014 (the biggest financial newspaper in Israel) - Google Translate

    MLV investment bank : "We believe that the Chief Scientist grant and approval of the FDA and EMA stem cell manufacturing facility in Haifa, gives PLURISTEM the ability to perform large clinical trials "
    U.S. investment bank MLV provides Pluristem's share price target of $ 6 to 12 months, compared with the closing price of 3.58 dollars on Wall Street on Friday. That is, a difference of about 67 %.
    Review issued by the investment he notes that the grant received should cover the investment in research and development in the coming year (2014). "We believe that the Chief Scientist grant and approval of FDA and EMA stem cell manufacturing facility in Haifa, gives PLURISTEM the ability to perform large clinical trials," says the review. Last week Pluristem received the approval of the Chief Scientist for a grant in the amount of NIS 14.6 million.
    MLV economists point out that the experiment began phase two of Pluristem South Korea indication of moderate intermittent claudication (IC), and the expectation for orphan drug status preeclampsia may be a catalyst to Pluristem's share in the near future. Review of MLV indicate that the approval of the manufacturing facility Pluristem regulatory authorities in the U.S. and Europe are important milestones that validates the company can perform extensive experiments and also validates the production platform capable of Pluristem as such commercial production for cell therapy programs . Indication of preeclampsia and the expected approval of the FDA to start phase 1 trial towards the end of the year. Due Cycle brief experiment preeclampsia (Extension pregnancy two days was considered significant, and an extension of one week was considered significant very) experimental results are expected in the first quarter of 2015.

3.29-0.23(-6.53%)Jul 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.